Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

[1]  A. Galosi,et al.  Biological Selection Criteria for Radical Prostatectomy , 2002, Annals of the New York Academy of Sciences.

[2]  B. Yin,et al.  Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene , 2002, International journal of cancer.

[3]  R. Bast,et al.  OVX1, macrophage‐colony stimulating factor, and CA‐125‐II as tumor markers for epithelial ovarian carcinoma , 2001, Cancer.

[4]  E J Pavlik,et al.  The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. , 2000, Gynecologic oncology.

[5]  Steven J Skates,et al.  Screening for ovarian cancer: a pilot randomised controlled trial , 1999, The Lancet.

[6]  R. Bast,et al.  Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. , 1999, Gynecologic oncology.

[7]  I. Jacobs,et al.  The Role of CA 125 in Screening for Ovarian Cancer , 1998, The International journal of biological markers.

[8]  L. Bottaci,et al.  Artificial neural networks applied to outcome prediction for colorectal cancer patients in separate institutions , 1997, The Lancet.

[9]  I. Jacobs,et al.  Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study , 1996, BMJ.

[10]  W. Baxt,et al.  Prospective validation of artificial neural network trained to identify acute myocardial infarction , 1996, The Lancet.

[11]  R. Bast,et al.  Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers , 1995, Cancer.

[12]  M R Conaway,et al.  Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. , 1995, Gynecologic oncology.

[13]  T. Bourne,et al.  Screening for early familial ovarian cancer with transvaginal ultrasonography and color blood flow imaging , 1994 .

[14]  R. Bast,et al.  Elevation of multiple serum markers in patients with stage I ovarian cancer. , 1993, Journal of the National Cancer Institute.

[15]  T. Bourne,et al.  Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. , 1993, BMJ.

[16]  R. Bast,et al.  Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[17]  R. Bast,et al.  An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. , 1988, Gynecologic oncology.

[18]  R. Bast,et al.  Preoperative Evaluation of Serum CA 125 Levels in Patients With Primary Epithelial Ovarian Cancer , 1986, Obstetrics and gynecology.

[19]  R. Bast,et al.  Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. , 1985, Gynecologic oncology.

[20]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[21]  G. Mills,et al.  Early detection of ovarian cancer: promise and reality. , 2002, Cancer treatment and research.

[22]  Y. Saito,et al.  Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. , 2000, Cancer.

[23]  Heekuck Oh,et al.  Neural Networks for Pattern Recognition , 1993, Adv. Comput..

[24]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.